Related Experiment Video
Updated: Jan 16, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
BNIP3L/NIX-mediated mitophagy: Future directions in Alzheimer's disease
Violina Kakoty1, Khang Wen Goh2, Prashant Kesharwani3
1School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T Road, Phagwara, Punjab, India.
Abstract:
BCL2-interacting protein 3 like (BNIP3L) /Nip3-like protein X (NIX) is a mitochondrial outer membrane protein possessing mitophagic and pro-apoptotic properties. Mitochondrial dysfunction and subsequent mitophagy impairment are some of the early triggers for Alzheimer's Disease (AD), which is a progressive neurodegenerative condition affecting memory, thinking, and behavior. AD is associated with mitochondrial protein impairment and mitophagy failure. A recent study showed downregulation in BNIP3L expression in response to stress hormone release during Alzheimer's, and pretreatment with a BNIP3L enhancer of a corticosterone-exposed mouse upregulated mitophagy. This research proved that BNIP3L stimulation can be an effective therapeutic strategy against Alzheimer's. However, BNIP3L-mediated mitophagy studies focused on Alzheimer's have been relatively scarce, and expanding knowledge on its regulatory proteins will help lay a smoother road ahead for future Alzheimer's research. In this review, we aim to summarize all the recent findings of the downstream proteins of BNIP3L, which play an indispensable role in inducing BNIP3L-mediated mitophagy effects. The review also explicates the significance of healthy mitochondria and normally functioning mitophagy in Alzheimer's. Finally, the review states the implications of BNIP3L in other diseases, like cardiovascular conditions and cancer, underscoring the immense potential of this wonder protein.
Insights
Stimulating BCL2-interacting protein 3 like (BNIP3L) may treat Alzheimer's Disease (AD). BNIP3L enhances mitophagy, a process crucial for clearing damaged mitochondria implicated in AD pathogenesis.
Area of Science:
- Cell Biology
- Neuroscience
- Biochemistry
Background:
- Mitochondrial dysfunction and impaired mitophagy are early indicators of Alzheimer's Disease (AD).
- BNIP3L (also known as NIX) is a mitochondrial protein involved in mitophagy and apoptosis.
- Reduced BNIP3L expression is observed in response to stress during Alzheimer's.
Purpose of the Study:
- To review downstream proteins of BNIP3L that mediate mitophagy.
- To highlight the role of healthy mitochondria and mitophagy in Alzheimer's Disease.
- To discuss the therapeutic potential of BNIP3L in AD and other diseases.
Main Methods:
- Literature review of recent findings on BNIP3L-mediated mitophagy.
- Analysis of studies investigating BNIP3L expression and function in Alzheimer's models.
- Synthesis of information on BNIP3L's role in mitochondrial health and disease.
Main Results:
- BNIP3L stimulation upregulates mitophagy, showing therapeutic promise for Alzheimer's.
- Downstream proteins of BNIP3L are critical for its mitophagy-inducing effects.
- BNIP3L has implications beyond AD, including cardiovascular conditions and cancer.
Conclusions:
- BNIP3L is a key regulator of mitophagy with significant therapeutic potential for Alzheimer's Disease.
- Understanding BNIP3L's regulatory network is crucial for advancing AD research.
- BNIP3L's multifaceted role underscores its potential as a therapeutic target in various diseases.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

